Covance Inc (CVD) 107.08 $CVD
Covance Has Returned 33.1% Since SmarTrend Recommendation (CVD)
Comtex SmarTrend(R) - Wed Feb 11, 9:43AM CST
SmarTrend identified an Uptrend for Covance (NYSE:CVD) on October 22nd, 2014 at $80.09. In approximately 4 months, Covance has returned 33.10% as of today's recent price of $106.59.
CVD: 107.08 (+0.05)
Strong And Under The Radar Today: Covance (CVD)
at The Street - Wed Feb 11, 9:26AM CST
Trade-Ideas LLC identified Covance (CVD) as a strong and under the radar candidate
CVD: 107.08 (+0.05)
Teledyne Technologies Set to Join the S&P MidCap 400; Popeyes Louisiana Kitchen, Iridium Communications to Join the S&P SmallCap 600
PR Newswire - Tue Feb 10, 5:04PM CST
S&P Dow Jones Indices will make the following changes to the S&P MidCap 400 and S&P SmallCap 600 indices:
DRIV: 25.99 (+0.06), IRDM: 9.46 (+0.11), TDY: 100.91 (+1.11), LH: 116.90 (+0.06), MHFI: 102.19 (unch), PLKI: 61.07 (+0.44), CVD: 107.08 (+0.05)
Covance Earnings in Line, LabCorp Merger Awaits Closure - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Feb 05, 8:36AM CST
Covance (CVD) delivered a healthy performance in the quarter, breaking all prior records, specifically with fourth quarter adjusted net orders amounting to $823 million.
ABCO: 53.69 (+0.32), BEAT: 10.36 (+0.20), LH: 116.90 (+0.06), CVD: 107.08 (+0.05)
Uptrend Call Working As Covance Stock Rises 33.2% (CVD)
Comtex SmarTrend(R) - Wed Feb 04, 9:10AM CST
SmarTrend identified an Uptrend for Covance (NYSE:CVD) on October 22nd, 2014 at $80.09. In approximately 4 months, Covance has returned 33.16% as of today's recent price of $106.64.
CVD: 107.08 (+0.05)
Covance ups earnings 14% in Q4
Seeking Alpha - at Seeking Alpha - Wed Feb 04, 9:04AM CST
CVD: 107.08 (+0.05)
Covance beats by $0.01, beats on revenue
Seeking Alpha - at Seeking Alpha - Wed Feb 04, 6:34AM CST
CVD: 107.08 (+0.05)
Covance Reports Fourth Quarter Net Revenue Of $634 Million, Pro Forma EPS Of $0.97 And Record Adjusted Net Orders Of $823 Million
PR Newswire - Wed Feb 04, 6:30AM CST
Covance Inc. (NYSE: CVD) today reported results for its fourth quarter ended December 31, 2014. Net revenue was $634 million, representing 1.8% growth on a GAAP basis from the fourth quarter of 2013. When adjusting for the impact of foreign exchange and the divestitures of the Seattle genomics laboratory and antibody products service line and the acquisition of Medaxial in 2014, revenue growth was 5.3% versus the fourth quarter of 2013. On a GAAP basis, the company reported earnings of $0.91 per diluted share in the fourth quarter. The company reported pro forma earnings per diluted share of $0.97, up 11.9% over the fourth quarter of 2013. Pro forma results exclude charges associated with restructuring and other cost reduction actions and expenses incurred in connection with the planned merger with Laboratory Corporation of America® Holdings (LabCorp®) (NYSE: LH) totaling $5.6 million or $0.06 per share.
LH: 116.90 (+0.06), CVD: 107.08 (+0.05)
Stocks Slide Into Closing Bell; Day's Winners: Amazon, Biogen
at Investor's Business Daily - Fri Jan 30, 4:08PM CST
The stock market today ended sharply lower after sliding off a midafternoon high. The Nasdaq fell 1%, despite a 14% gain by Amazon.com (AMZN) and a 10% surge by Biogen (BIIB). At the low end of the index, truckmaker Paccar (PCAR) dived 6%, Viacom...
AMZN: 381.83 (+4.66), BIIB: 391.66 (-0.45), PCAR: 64.22 (+0.98), DAL: 44.50 (-0.31), SYY: 39.54 (-0.12), XOM: 93.37 (+1.00), CVD: 107.08 (+0.05), PHM: 22.89 (+0.02), GOOGL: 551.16 (+5.15), MSFT: 43.87 (+0.78), VIAB: 68.98 (+1.27)
Icon, A Leader In Its Industry, Builds A Base
at Investor's Business Daily - Tue Jan 27, 5:12PM CST
New drugs require clinical trials and those trials increasingly have taken place on an international stage. Many top drug developers outsource an increasing share of trials to companies like Icon (ICLR). Based in Dublin, Icon is one of the top five...
PRXL: 62.91 (-0.18), Q: 63.31 (+0.06), LH: 116.90 (+0.06), ICLR: 60.01 (+0.38), CVD: 107.08 (+0.05)
Shares of CVD Up 33.0% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Tue Jan 27, 4:50PM CST
SmarTrend identified an Uptrend for Covance (NYSE:CVD) on October 22nd, 2014 at $80.09. In approximately 3 months, Covance has returned 33.02% as of today's recent price of $106.53.
CVD: 107.08 (+0.05)
LabCorp Prices $500,000,000 in 2.625% Senior Notes Due 2020, $500,000,000 in 3.200% Senior Notes Due 2022, $1,000,000,000 in 3.600% Senior Notes Due 2025 and $900,000,000 in 4.700% Senior Notes Due 2045
Business Wire - Wed Jan 21, 6:41PM CST
Laboratory Corporation of America(R) Holdings (LabCorp(R)) (NYSE: LH) announced today that it has priced its offering of $2.9 billion in senior notes. The offering consists of four tranches: $500,000,000 aggregate principal amount of 2.625% Senior Notes due 2020 (the "2020 Notes"
, $500,000,000 aggregate principal amount of 3.200% Senior Notes due 2022 (the "2022 Notes" , $1,000,000,000 aggregate principal amount of 3.600% Senior Notes due 2025 (the "2025 Notes" and $900,000,000 aggregate principal amount of 4.700% Senior Notes due 2045 (together with the 2020 Notes, the 2022 Notes and the 2025 Notes, the "Notes" . The Notes will bear interest from January 30, 2015, payable semi-annually on February 1 and August 1, commencing on August 1, 2015. The closing of the offering is expected to occur on January 30, 2015, subject to the satisfaction of customary closing conditions. The Notes will be senior unsecured obligations and will rank equally with LabCorp's existing and future senior unsecured debt.
LH: 116.90 (+0.06), CVD: 107.08 (+0.05)
LabCorp Announces Proposed Sale of Senior Notes
Business Wire - Wed Jan 21, 7:59AM CST
Laboratory Corporation of America(R) Holdings (LabCorp(R)) (NYSE: LH) announced today that it plans to offer, subject to market and other conditions, senior notes that are expected to be issued in four tranches with maturities of 5,7,10 and 30 years, respectively (the "Notes" . The Notes will be senior unsecured obligations and will rank equally with LabCorp's existing and future senior unsecured debt.
LH: 116.90 (+0.06), CVD: 107.08 (+0.05)
Covance Shares Up 33.1% Since SmarTrend's Buy Recommendation (CVD)
Comtex SmarTrend(R) - Tue Jan 20, 10:55AM CST
SmarTrend identified an Uptrend for Covance (NYSE:CVD) on October 22nd, 2014 at $80.08. In approximately 3 months, Covance has returned 33.10% as of today's recent price of $106.59.
CVD: 107.08 (+0.05)
Covance Launches New Solution to Bridge Preclinical to Clinical Development
PR Newswire - Tue Jan 20, 7:30AM CST
Covance Inc. (NYSE: CVD), the world's most comprehensive drug development company, today announced the introduction of Covance Early Phase Development Solutions, a multi-disciplined approach to early drug development that provides unmatched expertise, partnership and continuity to generate greater value in asset development and achieve accelerated delivery timelines.
CVD: 107.08 (+0.05)
Covance Sets February 18, 2015 As Date of Special Stockholder Meeting To Vote On Its Proposed Acquisition By Labcorp
PR Newswire - Mon Jan 12, 8:00AM CST
Covance Inc. (NYSE: CVD) today announced it has set a date for a special meeting of its stockholders to consider and vote on the previously announced proposed acquisition of Covance by Laboratory Corporation of America® Holdings (LabCorp®) (NYSE: LH) and certain other related matters. The special meeting will be held on February 18, 2015, at 8:00 a.m. local time, at the Princeton Marriott Hotel & Conference Center at Forrestal, 100 College Road East, Princeton, New Jersey.
LH: 116.90 (+0.06), CVD: 107.08 (+0.05)
Equities Updates on Health Care Sector - Johnson and Johnson, VIVUS, Actavis, Covance, and Sequenom
PR Newswire - Mon Jan 12, 7:35AM CST
Investor-Edge has initiated coverage on the following equities: Johnson and Johnson (NYSE: JNJ), VIVUS Inc. (NASDAQ: VVUS), Actavis PLC (NYSE: ACT), Covance Inc. (NYSE: CVD), and Sequenom Inc. (NASDAQ: SQNM). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Friday, January 09, 2015, the NASDAQ Composite ended at 4,704.07, down 0.68%, the Dow Jones Industrial Average declined 0.95%, to finish the day at 17,737.37, and the S&P 500 closed at 2,044.81, down 0.84%. The losses were broad based as all the sectors ended the session in negative. The S&P 500 Health Care Sector Index ended the day at 813.23, down 0.81%, while the index has surged 11.61% in the previous three months. Register for your complimentary reports on these five stocks at:
JNJ: 99.62 (+1.18), SQNM: 3.62 (unch), ACT: 285.37 (+3.71), VVUS: 2.68 (+0.13), CVD: 107.08 (+0.05)
Covance (CVD) Highlighted As Strong And Under The Radar Stock Of The Day
at The Street - Thu Jan 08, 8:45AM CST
Trade-Ideas LLC identified Covance (CVD) as a strong and under the radar candidate
CVD: 107.08 (+0.05)
Contract Research Organization (CRO) Market 2019 Global Forecasts in New Research Reports
PR Newswire - Wed Jan 07, 10:30AM CST
ReportsnReports.com adds "Global CRO Market 2015-2019" research report of 75 pages to the healthcare and pharmaceuticals industry intelligence collection of its online business research and data library.
PRXL: 62.91 (-0.18), PRAH: 27.19 (+0.31), CVD: 107.08 (+0.05)
Covance Has Returned 33.1% Since SmarTrend Recommendation (CVD)
Comtex SmarTrend(R) - Wed Feb 11, 9:43AM CST
SmarTrend identified an Uptrend for Covance (NYSE:CVD) on October 22nd, 2014 at $80.09. In approximately 4 months, Covance has returned 33.10% as of today's recent price of $106.59.
CVD: 107.08 (+0.05)
Strong And Under The Radar Today: Covance (CVD)
at The Street - Wed Feb 11, 9:26AM CST
Trade-Ideas LLC identified Covance (CVD) as a strong and under the radar candidate
CVD: 107.08 (+0.05)
Teledyne Technologies Set to Join the S&P MidCap 400; Popeyes Louisiana Kitchen, Iridium Communications to Join the S&P SmallCap 600
PR Newswire - Tue Feb 10, 5:04PM CST
S&P Dow Jones Indices will make the following changes to the S&P MidCap 400 and S&P SmallCap 600 indices:
DRIV: 25.99 (+0.06), IRDM: 9.46 (+0.11), TDY: 100.91 (+1.11), LH: 116.90 (+0.06), MHFI: 102.19 (unch), PLKI: 61.07 (+0.44), CVD: 107.08 (+0.05)
Covance Earnings in Line, LabCorp Merger Awaits Closure - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Feb 05, 8:36AM CST
Covance (CVD) delivered a healthy performance in the quarter, breaking all prior records, specifically with fourth quarter adjusted net orders amounting to $823 million.
ABCO: 53.69 (+0.32), BEAT: 10.36 (+0.20), LH: 116.90 (+0.06), CVD: 107.08 (+0.05)
Uptrend Call Working As Covance Stock Rises 33.2% (CVD)
Comtex SmarTrend(R) - Wed Feb 04, 9:10AM CST
SmarTrend identified an Uptrend for Covance (NYSE:CVD) on October 22nd, 2014 at $80.09. In approximately 4 months, Covance has returned 33.16% as of today's recent price of $106.64.
CVD: 107.08 (+0.05)
Covance ups earnings 14% in Q4
Seeking Alpha - at Seeking Alpha - Wed Feb 04, 9:04AM CST
CVD: 107.08 (+0.05)
Covance beats by $0.01, beats on revenue
Seeking Alpha - at Seeking Alpha - Wed Feb 04, 6:34AM CST
CVD: 107.08 (+0.05)
Covance Reports Fourth Quarter Net Revenue Of $634 Million, Pro Forma EPS Of $0.97 And Record Adjusted Net Orders Of $823 Million
PR Newswire - Wed Feb 04, 6:30AM CST
Covance Inc. (NYSE: CVD) today reported results for its fourth quarter ended December 31, 2014. Net revenue was $634 million, representing 1.8% growth on a GAAP basis from the fourth quarter of 2013. When adjusting for the impact of foreign exchange and the divestitures of the Seattle genomics laboratory and antibody products service line and the acquisition of Medaxial in 2014, revenue growth was 5.3% versus the fourth quarter of 2013. On a GAAP basis, the company reported earnings of $0.91 per diluted share in the fourth quarter. The company reported pro forma earnings per diluted share of $0.97, up 11.9% over the fourth quarter of 2013. Pro forma results exclude charges associated with restructuring and other cost reduction actions and expenses incurred in connection with the planned merger with Laboratory Corporation of America® Holdings (LabCorp®) (NYSE: LH) totaling $5.6 million or $0.06 per share.
LH: 116.90 (+0.06), CVD: 107.08 (+0.05)
Stocks Slide Into Closing Bell; Day's Winners: Amazon, Biogen
at Investor's Business Daily - Fri Jan 30, 4:08PM CST
The stock market today ended sharply lower after sliding off a midafternoon high. The Nasdaq fell 1%, despite a 14% gain by Amazon.com (AMZN) and a 10% surge by Biogen (BIIB). At the low end of the index, truckmaker Paccar (PCAR) dived 6%, Viacom...
AMZN: 381.83 (+4.66), BIIB: 391.66 (-0.45), PCAR: 64.22 (+0.98), DAL: 44.50 (-0.31), SYY: 39.54 (-0.12), XOM: 93.37 (+1.00), CVD: 107.08 (+0.05), PHM: 22.89 (+0.02), GOOGL: 551.16 (+5.15), MSFT: 43.87 (+0.78), VIAB: 68.98 (+1.27)
Icon, A Leader In Its Industry, Builds A Base
at Investor's Business Daily - Tue Jan 27, 5:12PM CST
New drugs require clinical trials and those trials increasingly have taken place on an international stage. Many top drug developers outsource an increasing share of trials to companies like Icon (ICLR). Based in Dublin, Icon is one of the top five...
PRXL: 62.91 (-0.18), Q: 63.31 (+0.06), LH: 116.90 (+0.06), ICLR: 60.01 (+0.38), CVD: 107.08 (+0.05)
Shares of CVD Up 33.0% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Tue Jan 27, 4:50PM CST
SmarTrend identified an Uptrend for Covance (NYSE:CVD) on October 22nd, 2014 at $80.09. In approximately 3 months, Covance has returned 33.02% as of today's recent price of $106.53.
CVD: 107.08 (+0.05)
LabCorp Prices $500,000,000 in 2.625% Senior Notes Due 2020, $500,000,000 in 3.200% Senior Notes Due 2022, $1,000,000,000 in 3.600% Senior Notes Due 2025 and $900,000,000 in 4.700% Senior Notes Due 2045
Business Wire - Wed Jan 21, 6:41PM CST
Laboratory Corporation of America(R) Holdings (LabCorp(R)) (NYSE: LH) announced today that it has priced its offering of $2.9 billion in senior notes. The offering consists of four tranches: $500,000,000 aggregate principal amount of 2.625% Senior Notes due 2020 (the "2020 Notes"
, $500,000,000 aggregate principal amount of 3.200% Senior Notes due 2022 (the "2022 Notes" , $1,000,000,000 aggregate principal amount of 3.600% Senior Notes due 2025 (the "2025 Notes" and $900,000,000 aggregate principal amount of 4.700% Senior Notes due 2045 (together with the 2020 Notes, the 2022 Notes and the 2025 Notes, the "Notes" . The Notes will bear interest from January 30, 2015, payable semi-annually on February 1 and August 1, commencing on August 1, 2015. The closing of the offering is expected to occur on January 30, 2015, subject to the satisfaction of customary closing conditions. The Notes will be senior unsecured obligations and will rank equally with LabCorp's existing and future senior unsecured debt. LH: 116.90 (+0.06), CVD: 107.08 (+0.05)
LabCorp Announces Proposed Sale of Senior Notes
Business Wire - Wed Jan 21, 7:59AM CST
Laboratory Corporation of America(R) Holdings (LabCorp(R)) (NYSE: LH) announced today that it plans to offer, subject to market and other conditions, senior notes that are expected to be issued in four tranches with maturities of 5,7,10 and 30 years, respectively (the "Notes"
. The Notes will be senior unsecured obligations and will rank equally with LabCorp's existing and future senior unsecured debt. LH: 116.90 (+0.06), CVD: 107.08 (+0.05)
Covance Shares Up 33.1% Since SmarTrend's Buy Recommendation (CVD)
Comtex SmarTrend(R) - Tue Jan 20, 10:55AM CST
SmarTrend identified an Uptrend for Covance (NYSE:CVD) on October 22nd, 2014 at $80.08. In approximately 3 months, Covance has returned 33.10% as of today's recent price of $106.59.
CVD: 107.08 (+0.05)
Covance Launches New Solution to Bridge Preclinical to Clinical Development
PR Newswire - Tue Jan 20, 7:30AM CST
Covance Inc. (NYSE: CVD), the world's most comprehensive drug development company, today announced the introduction of Covance Early Phase Development Solutions, a multi-disciplined approach to early drug development that provides unmatched expertise, partnership and continuity to generate greater value in asset development and achieve accelerated delivery timelines.
CVD: 107.08 (+0.05)
Covance Sets February 18, 2015 As Date of Special Stockholder Meeting To Vote On Its Proposed Acquisition By Labcorp
PR Newswire - Mon Jan 12, 8:00AM CST
Covance Inc. (NYSE: CVD) today announced it has set a date for a special meeting of its stockholders to consider and vote on the previously announced proposed acquisition of Covance by Laboratory Corporation of America® Holdings (LabCorp®) (NYSE: LH) and certain other related matters. The special meeting will be held on February 18, 2015, at 8:00 a.m. local time, at the Princeton Marriott Hotel & Conference Center at Forrestal, 100 College Road East, Princeton, New Jersey.
LH: 116.90 (+0.06), CVD: 107.08 (+0.05)
Equities Updates on Health Care Sector - Johnson and Johnson, VIVUS, Actavis, Covance, and Sequenom
PR Newswire - Mon Jan 12, 7:35AM CST
Investor-Edge has initiated coverage on the following equities: Johnson and Johnson (NYSE: JNJ), VIVUS Inc. (NASDAQ: VVUS), Actavis PLC (NYSE: ACT), Covance Inc. (NYSE: CVD), and Sequenom Inc. (NASDAQ: SQNM). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Friday, January 09, 2015, the NASDAQ Composite ended at 4,704.07, down 0.68%, the Dow Jones Industrial Average declined 0.95%, to finish the day at 17,737.37, and the S&P 500 closed at 2,044.81, down 0.84%. The losses were broad based as all the sectors ended the session in negative. The S&P 500 Health Care Sector Index ended the day at 813.23, down 0.81%, while the index has surged 11.61% in the previous three months. Register for your complimentary reports on these five stocks at:
JNJ: 99.62 (+1.18), SQNM: 3.62 (unch), ACT: 285.37 (+3.71), VVUS: 2.68 (+0.13), CVD: 107.08 (+0.05)
Covance (CVD) Highlighted As Strong And Under The Radar Stock Of The Day
at The Street - Thu Jan 08, 8:45AM CST
Trade-Ideas LLC identified Covance (CVD) as a strong and under the radar candidate
CVD: 107.08 (+0.05)
Contract Research Organization (CRO) Market 2019 Global Forecasts in New Research Reports
PR Newswire - Wed Jan 07, 10:30AM CST
ReportsnReports.com adds "Global CRO Market 2015-2019" research report of 75 pages to the healthcare and pharmaceuticals industry intelligence collection of its online business research and data library.
PRXL: 62.91 (-0.18), PRAH: 27.19 (+0.31), CVD: 107.08 (+0.05)
